Clinical trial NCT04696354: Intravascular Ultrasound-Guided Intervention for Venous Leg Ulcers (IGuideU)
Official title: Intravascular Ultrasound-Guided Intervention for Venous Leg Ulcers
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Venous Ulcer of Leg
Keywords: VLU
venous leg ulcer
ulcer
venous leg wound
venous stenting
IVUS
DVO
Lead sponsor: Philips Clinical & Medical Affairs Global
Sponsor class: INDUSTRY
First posted: 2021-01-06
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This clinical study is a global, prospective, multi-center, randomized controlled trial to determine if the use of intravascular ultrasound (IVUS) as an adjunctive imaging modality and as an interventional treatment guide will result in a more accurate diagnosis of deep vein occlusion (DVO), will guide optimal therapy, and will provide better clinical outcomes with reduced cost of care for patients presenting with persistent venous leg ulcers (VLUs).

Detailed description: This study will be conducted in 266 subjects presenting with venous ulcers that have previously undergone treatment for superficial of and/or perforator venous disease, if clinically indicated, followed by at least 3 months of prescribed compression therapy prior to screening.

There are 6 study visits for each subject that will be completed over a period lasting approximately 24 months. Subjects will undergo a baseline/screening assessment (visit 1) followed by an interrogation procedure (visit 2) if the subject is enrolled into the interrogation arm. If the subject is randomized to the deferred interrogation arm, he/she will have a hospital/office visit in lieu of the interrogation procedure, which will be considered visit 2. For statistical purposes, the wound assessment performed at the index procedure/hospital visit will be considered the baseline measurement. 30±14 days and 90±14 days after Visit 2, the subject will return to the office for a 1- and 3-month follow-up visit, respectively. The subjects will return at 6- and 12-months post-index procedure/Visit 2 for follow-up assessments. The follow-up period for this study will be approximately 24 months, with a phone call only at 24-months post-index procedure/visit 2.

The clinical study has a planned enrollment period of 36 months and a planned study duration period of 5.17 years

Eligibility criteria: Inclusion Criteria:

* Be between 18 and 85 years of age.
* Able and willing to participate and comply with the protocol, including the defined follow-up schedule, by signing an Institutional Review Board (IRB) or Ethics Committee approved informed consent form.
* Active venous leg ulcer (CEAP C6).
* Previously completed treatment for clinically significant reflux in the superficial and/or perforator venous system of the target limb at least 3 months prior to enrollment, if clinically indicated.
* Completed at least 3 months of prescribed compression therapy after any ablation.
* Palpable dorsalis pedis or posterior tibial artery (DP/PT) pulses at ipsilateral foot or ankle brachial index (ABI) ≥0.8.
* Be able to ambulate unassisted or with non-motorized assistive devices.
* Current VLU present ≤48 months.

Exclusion Criteria:

* Patient is known pregnant or breast-feeding or planning to become pregnant in the following year.
* If antiplatelet and anticoagulation therapy cannot be tolerated.
* Previous venous stent implantation involving the target limb, target lesion, or inferior vena cava.
* Previous venovenous bypass surgery involving the target limb.
* Previous endovascular recanalization of the target lesion segment.
* Known metal allergy precluding stent implantation.
* Known or suspected to have inadequate inflow to support stent patency in the target limb.
* Active cancer diagnosis.
* Known positive test for COVID-19 (Sars-CoV-2) within the last 2 weeks and actively symptomatic.
* Known or suspected venous outflow obstruction caused by tumor compression/encasement with or without thrombus.
* Known allergy to contrast media that cannot adequately be pre-medicated prior to study procedure.
* Known renal dysfunction (defined as eGFR \<30mL/min/1.73m2) that would preclude adequate contrast usage.
* Diagnosed with right heart failure/pulmonary hypertension.
* Has known clinically significant abnormal platelet count outside laboratory reference ranges.
* Has known clinically significant abnormal white blood cell count (WBC), fever, sepsis or positive blood culture.
* Organ transplant requiring immunosuppressant therapy.
* Unstable angina pectoris, or myocardial infarction within 30 days and/or hemorrhagic stroke within 3 months.
* Subjects with an active diagnosis of osteomyelitis of the ipsilateral limb.
* Previous or planned surgical or catheter-based procedure on index leg within 30 days before or 30 days after the index procedure.
* Active participation in another investigational drug or device study.
* Subject has any condition, which, in the opinion of the investigator, precludes the subject from participation.

Primary outcomes:
measure: Rate of Detection and Difference in Complete Ulcer Healing Between the Interrogation Group and the Deferred Interrogation Group
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Darien
country: United States
facility: Vascular Care Connecticut
state: Connecticut
city: Winter Park
country: United States
facility: Florida Cardiology, P.A.
state: Florida
city: Chicago
country: United States
facility: Northwestern
state: Illinois
city: Houma
country: United States
facility: Cardiovascular Institute of the South
state: Louisiana
city: Lake Charles
country: United States
facility: Vein Center of Southwest Louisiana
state: Louisiana
city: Englewood
country: United States
facility: Englewood Hospital and Medical Center
state: New Jersey
city: New York
country: United States
facility: NYU Langone Health
state: New York
city: Charlotte
country: United States
facility: Atrium Health
state: North Carolina
city: Wollongong
country: Australia
facility: Wollongong Hospital
state: New South Wales
city: Perth
country: Australia
facility: Royal Perth Hospital
state: Western Australia
city: Strasbourg
country: France
facility: CHU Strasbourg
state: Alsace
city: Vichy
country: France
facility: CH Vichy
state: Bourbonnais
city: Dijon
country: France
facility: C.H.U. Dijon
city: Arnsberg
country: Germany
facility: Klinikum Hochsauerland GmbH
state: North Rhine-Westphalia
city: Harrow
country: United Kingdom
facility: Northwick Park Hospital
state: London
city: Hampstead
country: United Kingdom
facility: Royal Free London NHS Foundation Trust
city: London
country: United Kingdom
facility: Guys and St. Thomas' Hospital
Study officials:
affiliation: St. Thomas and Guys Hospital
name: Stephen Black, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Vascular Care CT, PLLC
name: Paul Gagne, MD
role: PRINCIPAL_INVESTIGATOR
References: